US › Healthcare

Tvardi Therapeutics, Inc. (TVRD)

US · Healthcare · Biotechnology

$1.62-6.36%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-6.5M

Profit YoY

-255.0%

EPS

$-0.69

EPS estimate

$-0.65

EPS came in at -0.69 against a street estimate of -0.65 — a miss of 6.2%.

Key statistics

Market cap

$24.5M

Forward P/E

0.0

P/B

2.94

Book value

$1.55

EPS (TTM)

$-2.87

52-week high

$43.65

52-week low

$1.50

50-day MA

$2.27

200-day MA

$3.30

Analyst view

Analysts rate Tvardi Therapeutics, Inc. a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $9.50.

Shareholding

Insiders

24.36%

Institutions

17.34%

Largest institutional holders

Fund	Stake
Slate Path Capital LP	5.28%
BlackRock Inc	2.91%
Vanguard Capital Management, LLC	2.58%
American Financial Group Inc	1.68%
Geode Capital Management, LLC	1.37%
Silvercrest Asset Management Group LLC	0.76%
State Street Corp	0.73%
Renaissance Technologies Corp	0.69%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tvardi Therapeutics, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.